濕黴素(Hygromycin B) | CAS#31282-04-9 APExBIO貨號A2515
| 代理廠牌： |  |
| 原廠連結： | |
| 相關下載： |
特點
抗菌劑系列商品->>濕黴素(Hygromycin B)
APExBIO Technology LLC 是一家領先的小分子抑制劑 (Small Molecule Inhibitors)/活化劑(Activators)、化合物庫( Compound Libraries)、胜肽(Peptides)、檢測試劑盒(Assay Kits)、螢光標記(Fluorescent Label)、酶(Enzymes)、修飾核苷酸(Modified Nucleotides)、mRNA 合成以及各種分子生物學工具的供應商。APExBIO提供廣泛的產品線，涵蓋 20 多個不同的研究領域，例如癌症(cancer)、免疫學(immunology)、神經科學(neurosciences)、細胞凋亡(apoptosis)和表觀遺傳學(epigenetics)等。公司總部位於美國德州休士頓USA (Houston, Texas)，致力於服務全球客戶。高度重視產品品質。所有產品均遵循嚴格的生產指南，並附有分析證書、HPLC、質譜(Mass Spectrum)和HMNR以及體外驗證(in vitro validation)。 APExBIO產品已被《Nature》、《Cell》和《Science》等眾多頂級同行評審期刊引用。>>更多APExBio商品
濕黴素(Hygromycin B) | CAS#31282-04-9 APExBIO貨號A2515
Hygromycin B is a selective antibiotic.
抗生素(Antibiotics)是一種用於治療和預防細菌感染的抗菌劑。濕黴素(Hygromycin B)是一種選擇性抗生素。對大多數細菌(bacteria)、真菌和高等真核生物有效的抗生素。 濕黴素(Hygromycin B) 在 30S 亞基內有一個單一的結合位點，這與其單相效應一致。結合位點以高度序列特異性的方式位於螺旋的大溝中濕黴素(Hygromycin B)通過抑制延伸的易位步驟並導致 70S 核醣體中 mRNA 的錯誤翻譯來抑制蛋白質合成 [1]。 Hygromycin B 選擇性抑制 70S 核醣體上核醣體 ATP 酶 (RbbA) 的活性，並在生理濃度下從 70S 核醣體釋放 RbbA。 RbbA 增強 16S rRNA 開關螺旋區域的 A889 和 G890 的反應性。此外，濕黴素(Hygromycin B) 在解碼區保護 G1494 和 A1408。
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 527.5 |
| Cas No. | 31282-04-9 |
| Formula | C20H37N3O13 |
| Solubility | ≥26.38 mg/mL in H2O; ≥5.35 mg/mL in EtOH; ≥9.14 mg/mL in DMSO |
| Chemical Name | (3’R,3aS,4S,4’R,5’R,6R,6’R,7S,7aS)-4-[(1R,2S,3R,5S,6R)-3-amino-2,6-dihydroxy-5-(methylamino)cyclohexyl]oxy-6′-[(1S)-1-amino-2-hydroxyethyl]-6-(hydroxymethyl)spiro[4,6,7,7a-tetrahydro-3aH-[1,3]dioxolo[4,5-c]pyran-2,2′-oxane]-3′,4′,5′,7-tetrol |
| SDF | Download SDF |
| Canonical SMILES | CNC1CC(C(C(C1O)OC2C3C(C(C(O2)CO)O)OC4(O3)C(C(C(C(O4)C(CO)N)O)O)O)O)N |
| Shipping Condition | Ship with blue ice, or upon other requests. |
| General tips | For obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while. We do not recommend long-term storage for the solution, please use it up soon. |
APExBIO台灣代理商: https://www.apexbt.com/
APExBIO提供優質的胜肽和生物分析試劑，廣泛產品線如Protease、Chromatin/Epigenetics表觀遺傳學、MAPK Signal、DNA Damege/DNA repair、細胞凋亡、腫瘤生物學、Stem cell等研究領域， 還提供定制的服務，包括多肽合成，抗體的生產和檢測的發展。產品線DNA/RNA prep kit、Drug Screening panel、Bioactive peptides、Growth factors、Biotinylation Reagents、tag peptides、amino Acids、Growth factors等。APExBIO產品質量都伴隨著證書的分析，高效液相色譜，質譜，和HMNR數據。
| Cat# | Product Name |
| A8743 | SYBR Safe DNA Gel Stain |
| A6001 | 3X (DYKDDDDK) Peptide |
| K1018 | Cell Counting Kit-8 (CCK-8) |
| A1902 | Z-VAD-FMK |
| A3008 | Y-27632 dihydrochloride |
| A6002 | DYKDDDDK tag Peptide |
| B8362 | 2’3′-cGAMP (sodium salt) |
| F4002 | Phos binding reagent (Phosbind) acrylamide |
| A8011 | Biotin-tyramide |
| A2585 | MG-132 |
| F4005 | Prestained Protein Marker (Triple color, EDTA free, 10-250 kDa) |
| B1274 | AP20187 |
| K1007 | Protease Inhibitor Cocktail(EDTA-Free,100X in DMSO) |
| B8226 | InstaBlue Protein Stain Solution |
| A3011 | CHIR-99021 (CT99021) |
| A3007 | ABT-263 (Navitoclax) |
| B1524 | Erastin |
| B6055 | TCEP hydrochloride |
| K1031 | Phusion high-fidelity DNA polymerase |
| B1387 | (-)-Blebbistatin |
| B4664 | T-5224 |
| A8183 | Trichostatin A (TSA) |
| B3699 | ISRIB (trans-isomer) |
| A1910 | Bromodomain Inhibitor, (+)-JQ1 |
| B1293 | Y-27632 |
| A8167 | Rapamycin (Sirolimus) |
| A7024 | HOAt |
| A7025 | HOBt (anhydrous) |
| A8331 | Bleomycin Sulfate |
| A4333 | CPI-613 |
| K1070 | 2X SYBR Green qPCR Master Mix |
| A8005 | Sulfo-NHS-SS-Biotin |
| B4653 | BV6 |
| B5965 | Tamoxifen |
| A1901 | Q-VD-OPh hydrate |
| A8950 | UM 171 |
| K1046 | RNase Inhibitor, Murine |
| A3317 | Clozapine N-oxide (CNO) |
| A2614 | Bortezomib (PS-341) |
| A8003 | Sulfo-NHS-LC-Biotin |
| A4154 | Olaparib (AZD2281, Ku-0059436) |
| A8012 | Biotin-XX Tyramide Reagent |
| K1101 | PreScission Protease (PSP) |
| A8627 | Bafilomycin A1 |
| A8001 | Sulfo-NHS-Biotin |
| A3017 | Dasatinib (BMS-354825) |
| A2576 | E-64 |
| K1051 | Cy3 TSA Fluorescence System Kit |
| K1034 | 2X Taq PCR Master Mix (with dye) |
| B7972 | Pseudo-UTP |
| A8173 | Romidepsin (FK228, depsipeptide) |
| A4219 | Birinapant (TL32711) |
| A4371 | Ferrostatin-1 (Fer-1) |
| A8200 | DAPT (GSI-IX) |
| A8249 | SB 431542 |
| K1008 | Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) |
| A3133 | A 83-01 |
| A8192 | Staurosporine |
| B1054 | Resiquimod (R-848) |
| A3018 | Trametinib (GSK1120212) |
| A8184 | AICAR |
| K1025 | Direct Mouse Genotyping Kit |
| A2606 | Epoxomicin |
| A6006 | Hexa His tag peptide |
| A4393 | Paclitaxel (Taxol) |
| A8315 | NU7441 (KU-57788) |
| A4213 | Necrostatin-1 |
| A8885 | Ro 3306 |
| L1021 | DiscoveryProbe™ FDA-approved Drug Library |
| B1464 | KPT-330 |
| A8815 | SM-164 |
| B4879 | Blasticidin S HCl |
| A8793 | N3-kethoxal |
| K1047 | HyperScribe™ T7 High Yield RNA Synthesis Kit |
| A6004 | Influenza Hemagglutinin (HA) Peptide |
| B1036 | MLN4924 |
| A8178 | Panobinostat (LBH589) |
| A3963 | A-769662 |
| A3847 | SU5416 |
| B3252 | Dorsomorphin (Compound C) |
| B4758 | BAPTA-AM |
| A2513 | Geneticin, G-418 Sulfate |
| B6004 | PX-478 2HCl |
| A8955 | Z-YVAD-FMK |
| A8193 | ABT-737 |
| B2083 | Caspofungin Acetate |
| A8002 | NHS-Biotin |
| A8337 | CX-5461 |
| A8312 | Torin 1 |
| A2570 | Leupeptin, Microbial |
| K2170 | Alanine Aminotransferase (ALT or SGPT) Activity Colorimetric/Fluorometric Assay Kit |
| A4381 | FK866 (APO866) |
| B2143 | Tacrolimus (FK506) |
| A2571 | Pepstatin A |
| k1072 | First-Strand cDNA Synthesis Kit |
| A3003 | MDV3100 (Enzalutamide) |
| B5997 | Dyngo-4a |
| A3742 | Pyridostatin |
| A3173 | AMD-070 | 558447-26-0 | 98.00% | CXCR4 antagonist,potent and selective |
| A3174 | AMD-070 hydrochloride | 880549-30-4 | 98.00% | CXCR4 antagonist,potent and selective |
| A3176 | Ampalex | 154235-83-3 | 98.54% | Ampakine and nootropic |
| A3177 | AN-2690 | 174671-46-6 | 98.60% | Antifungal agent |
| A3178 | AN-2728 | 906673-24-3 | 99.33% | PDE4 inhibitor,anti-inflammatory compound |
| A3179 | Anamorelin | 249921-19-5 | 99.68% | Ghrelin receptor agonist, synthetic, orally active |
| A3182 | Anguizole | 442666-98-0 | 98.00% | Inhibitor of HCV replication |
| A3184 | AR-A014418 | 487021-52-3 | 98.34% | GSK3β inhibitor, ATP-competitive and selective |
| A3185 | AR-C155858 | 496791-37-8 | 99.52% | MCT1 and MCT2 inhibitor |
| A3188 | ARRY-520 R enantiomer | 885060-08-2 | 98.00% | KSP inhibitor |
| A3189 | AS 602801 | 848344-36-5 | 98.72% | Jun Kinase Inhibitor |
| A3190 | ASC-J9 | 52328-98-0 | 98.00% | AR degradation enhancer,antiumor agent |
| A3191 | Ascomycin(FK 520) | 104987-12-4 | 98.00% | Macrolide immunosuppressant,FK-520 analog |
| A3192 | Asenapine hydrochloride | 1412458-61-7 | 98.00% | Atypical antipsychotic |
| A3193 | ASP3026 | 1097917-15-1 | 99.38% | ALK inhibitor,potent and selective |
| A3194 | AST 487 | 630124-46-8 | 99.29% | RET kinase inhibitor |
| A3195 | Asunaprevir (BMS-650032) | 630420-16-5 | 99.80% | NS3 protease inhibitor |
| A3196 | AT-101 | 90141-22-3 | 98.00% | BH3-mimetic,gossypol enantiomer |
| A3197 | AT7519 Hydrochloride | 902135-91-5 | 99.80% | Multi-CDK inhibitor |
| A3198 | AT7519 trifluoroacetate | 1431697-85-6 | 98.00% | CDK/cyclin inhibitor |
| A3199 | AT7867 dihydrochloride | 1431697-86-7 | 98.00% | Akt1 and p70S6K/PKA inhibitor |
| A3201 | Atrasentan hydrochloride | 195733-43-8 | 98.00% | Endothelin receptor antagonist |
| A3202 | Avermectin B1 | 71751-41-2 | 98.00% | Insecticide |
| A3206 | AVL-292 | 1202757-89-8 | 98.27% | Btk inhibitor |
| A3208 | Avosentan | 290815-26-8 | 98.00% | ETA receptor antagonist |
| A3209 | AXL1717 | 477-47-4 | 98.07% | IGF-1R inhibitor,orally active |
| A3210 | AZ20 | 1233339-22-4 | 99.93% | ATR inhibitor,potent and selective |
| A3214 | AZD1152 | 722543-31-9 | 98.78% | Aurora B kinase inhibitor,highly potent and selective |
| A3215 | AZD7687 | 1166827-44-6 | 98.00% | DGAT inhibitor,potent and selective |
| A3216 | Balaglitazone | 199113-98-9 | 99.62% | PPAR-γ partial agonist |
| A3217 | Balapiravir | 690270-29-2 | 98.00% | Polymerase inhibitor,anti-HCV |
| A3218 | BAM7 | 331244-89-4 | 98.00% | BAX activator,direct and selective |
| A3219 | BAN ORL 24 | 475150-69-7 | 98.00% | NOP receptor antagonist, potent and selective |
| A3220 | Bardoxolone | 218600-44-3 | 99.55% | Once-a-day treatment for CKD |
| A3221 | Bardoxolone methyl | 218600-53-4 | 98.75% | IKK inhibitor, potent antioxidant inflammation modulator |
| A3222 | Baricitinib phosphate | 1187595-84-1 | 99.59% | JAK1/JAK2 inhibitor |
| A3227 | BAY 61-3606 | 732983-37-8 | 98.45% | Syk Inhibitor |
| A3228 | BAY 61-3606 dihydrochloride | 648903-57-5 | 98.00% | Syk tyrosine kinase inhibitor |
| A3230 | Bay 65-1942 HCl salt | 600734-06-3 | 98.00% | IKKβ kinase inhibitor |
| A3232 | Bazedoxifene | 198481-32-2 | 98.00% | Estrogen receptor modulator |
| A3236 | Benfotiamine | 22457-89-2 | 99.76% | Drug for painful nerve condition |
| A3237 | Betulinic acid | 472-15-1 | 98.00% | Anti-HIV and antitumor compound,pentacyclic triterpenoid |
| A3238 | BEZ235 Tosylate | 1028385-32-1 | 98.28% | MTOR/P13K inhibitor |
| A3239 | B-HT 920 | 36085-73-1 | 98.00% | D2 receptor agonist |
| A3240 | BIBX 1382 | 196612-93-8 | 98.00% | EGFR inhibitor,potent and selective |
| A3241 | Bilobalide | 33570-04-6 | 98.00% | Neuroprotective agent |
| A3242 | Bitopertin | 845614-11-1 | 99.70% | Glycine reuptake inhibitor(GlyT1) |
| A3244 | Bivalirudin Trifluoroacetate | 128270-60-0 | 98.07% | Reversible thrombin inhibitor |
| A3246 | BMN-673 8R,9S | 1207456-00-5 | 99.75% | Inactive form of BMN 673, used as negative control |
| A3248 | BMS345541 hydrochloride | 547757-23-3 | 99.57% | IKK inhibitor,highly selective |
| A3250 | BMS-509744 | 439575-02-7 | 98.00% | Itk inhibitor,potent and selective |
| A3252 | BMS-599626 Hydrochloride | 873837-23-1 | 99.58% | EGFR/HER2 inhibitor,potent and selective |
| A3253 | BMS-626529 | 701213-36-7 | 98.01% | HIV-1 attachment inhibitor |
| A3254 | BMS-663068 | 864953-29-7 | 98.00% | HIV-1 attachment inhibitor |
| A3256 | BMS-690514 | 859853-30-8 | 98.00% | HER/EGFR inhibitor |
| A3257 | BMS-790052 dihydrochloride | 1009119-65-6 | 99.81% | HCV NS5A inhibitor |
| A3258 | BMS-833923 | 1059734-66-5 | 99.84% | Smoothened inhibitor |
| A3259 | BMS-927711 | 1289023-67-1 | 98.99% | CGRP receptor antagonist |
| A3260 | BMX-IN-1 | 1431525-23-3 | 97.99% | BMX (also termed ETK) kinase inhibitor |
| A3261 | Boceprevir | 394730-60-0 | 98.00% | HCV protease inhibitor,potent and selective |
| A3263 | BRAF inhibitor | 918505-61-0 | 98.00% | Potent B-raf inhibitor |
| A3264 | B-Raf inhibitor | 1315330-11-0 | 98.00% | A B-Raf inhibitor |
| A3265 | Brassinolide | 72962-43-7 | 98.00% | Plant growth regulator |
| A3266 | BS-181 | 1092443-52-1 | 98.00% | CDK7 inhibitor,highly selective |
| A3268 | CAL-130 Hydrochloride | 1431697-78-7 | 98.00% | PI3K inhibitor |
| A3270 | Calcifediol monohydrate | 63283-36-3 | 99.43% | Prehormone;vitamin D3 metabolite |
| A3271 | Calcipotriol | 112965-21-6 | 98.00% | Vitamin D3 analog,regulates cell differentiation and proliferation |
| A3275 | Calcium-Sensing Receptor Antagonists I | 478963-79-0 | 98.00% | CaSR antagonist |
| A3276 | Canertinib dihydrochloride | 289499-45-2 | 99.72% | Pan-ErbB inhibitor, potent and selective |
| A3277 | Capadenoson | 544417-40-5 | 98.00% | Adenosine A1 receptor agonist |
| A3278 | Nonivamide (Capsaicin Analog) | 2444-46-4 | 99.53% | TRPV1 receptor agonist |
| A3279 | Capsazepine | 138977-28-3 | 99.25% | TRPV1 ion channel antagonist |
| A3282 | Cariprazine | 839712-12-8 | 99.19% | D2/D3 partial agonist,antipsychotic drug |
| A3284 | Cathepsin S inhibitor | 1373215-15-6 | 98.33% | Blocks MHCII antigen presentation |
| A3285 | CB 300919 | 289715-28-2 | 98.00% | Potential therapy for ovarian cancer |
| A3286 | CB30865 | 206275-15-2 | 98.00% | Nampt inhibitor |
| A3287 | CC-401 hydrochloride | 1438391-30-0 | 98.00% | JNK inhibitor |
| A3288 | CC-930 | 899805-25-5 | 98.00% | JNK inhibitor,potent and selective |
| A3289 | CCG-63802 | 620112-78-9 | 98.00% | RGS protein inhibitor |
| A3290 | CCG-63808 | 620113-73-7 | 98.00% | Reversible RGS inhibitor |
| A3291 | CCT241533 | 1262849-73-9 | 98.00% | Potent Chk2 inhibitor |
| A3292 | CCT241533 hydrochloride | 1431697-96-9 | 98.00% | CHK2 kinase inhibitor, novel |
| A3293 | CDK inhibitor II | 1269815-17-9 | 98.00% | CDK inhibitor |
| A3294 | CDK9 inhibitor | 1415559-43-1 | 98.00% | CDK9 inhibitor |
| A3295 | CDK9 inhibitor 2 | 1263369-28-3 | 98.00% | CDK9 inhibitor |
| A3297 | CEP-32496 hydrochloride | 1227678-26-3 | 98.00% | B-Raf/C-Raf inhibitor,highly potent |
| A3297 | CEP-32496 hydrochloride | 1227678-26-3 | 98.00% | B-Raf/C-Raf inhibitor,highly potent |
| A3298 | Cetirizine | 83881-51-0 | 99.65% | Antihistamine |
| A3300 | Cevimeline hydrochloride hemihydrate | 153504-70-2 | 98.00% | Agonist of muscarinic receptor (M1/M3) |
| A3302 | CGI-1746 | 910232-84-7 | 98.00% | Btk inhibitor |
| A3303 | CGP60474 | 164658-13-3 | 98.00% | CDKs and PKC inhibitor, potent |
| A3304 | CGS 21680 | 120225-54-9 | 98.00% | Adenosine A2 receptor agonists,potent and selective |
| A3305 | CHAPS | 75621-03-3 | 97.71% | Zwitterionic detergent for membrane proteins,nondenaturing |
| A3306 | Chelerythrine Chloride | 3895-92-9 | 99.36% | PKC antagonist |
| A3307 | CHIR-090 | 728865-23-4 | 99.37% | Potent LpxC inhibitor |
| A3308 | Choline Fenofibrate | 856676-23-8 | 99.92% | Choline salt of fenofibric acid |
| A3309 | CHR-6494 | 1333377-65-3 | 98.00% | Haspin inhibitor,potent ands selective |
| A3310 | chroman 1 | 1273579-40-0 | 98.00% | ROCK II inhibitor, highly potent and selective |
| A3311 | CID-2858522 | 758679-97-9 | 98.00% | NF-κB pathway inhibitor |
| A3313 | Cinacalcet | 226256-56-0 | 99.48% | Calcimimetic agent,orally active |
| A3314 | Cinaciguat | 329773-35-5 | 98.00% | Soluble guanylate cyclase (sGC) activators |
| A3315 | Clemizole | 442-52-4 | 99.06% | H1 histamine receptor antagonist |
| A3316 | Clemizole hydrochloride | 1163-36-6 | 99.73% | H1 histamine receptor antagonist |
| A3317 | Clozapine N-oxide (CNO) | 34233-69-7 | 99.74% | Metabolite of clozapine, used in chemogenetics. |
| A3319 | CMK | 821794-90-5 | 98.00% | RSK2 kinase inhibitor |
| A3320 | CO-1686 (AVL-301) | 1374640-70-6 | 99.28% | EGFR inhibitor |
| A3321 | Cobimetinib | 934660-93-2 | 99.71% | Selective MEK inhibitor |
| A3322 | Cobimetinib (racemate) | 934662-91-6 | 98.00% | Selective MEK inhibitor |
| A3331 | CP-809101 hydrochloride | 1215721-40-6 | 98.00% | 5-HT2C receptor agonist, potent and selective |
| A3334 | CTS-1027 | 193022-04-7 | 98.00% | MMPs inhibitor |
| A3335 | Curcumin | 458-37-7 | 98.36% | Tyrosinase inhibitor |
| A3336 | CVT-313 | 199986-75-9 | 98.04% | Cdk2 inhibitor |
| A3337 | CX-6258 | 1202916-90-2 | 98.28% | Pan-Pim kinases Inhibitor |
| A3339 | CYT387 sulfate salt | 1056636-06-6 | 98.00% | JAK1/JAK2 inhibitor |
| A3340 | CZC24832 | 1159824-67-5 | 98.00% | Selective PI3K-γ inhibitor |
| A3342 | D4476 | 301836-43-1 | 99.22% | CK1/ALK5 inhibitor,specific and cell permeable |
| A3343 | D609 | 83373-60-8 | 98.00% | PC-PLC inhibitor |
| A3344 | D-64131 | 74588-78-6 | 98.00% | Tubulin polymerization inhibitor |
| A3345 | Dabigatran etexilate mesylate | 872728-81-9 | 99.41% | Direct thrombin inhibitor,anticoagulant,prodrug of dabigatran |
| A3346 | Dabigatran ethyl ester | 429658-95-7 | 98.00% | Thrombin activity inhibitor |
| A3347 | Dabrafenib Mesylate (GSK-2118436) | 1195768-06-9 | 99.78% | Inhibitor of BRAF(V600) mutants |
| A3348 | Daminozide | 1596-84-5 | 98.00% | KDM2A inhibitor |
| A3349 | Darapladib | 356057-34-6 | 99.54% | Lp-PLA2 inhibitor, selective and orally active |
| A3351 | Dasatinib hydrochloride | 854001-07-3 | 99.91% | Multi-BCR/Abl and Src kinase inhibitor, oral active |
| A3352 | Daun02 | 290304-24-4 | 98.00% | Cell viability inhibitor,DNA synthisis inhibitor |
| A3353 | DB07268 | 929007-72-7 | 98.84% | JNK1 inhibitor |
| A3355 | Deferasirox Fe3+ chelate | 554435-83-5 | 98.00% | Oral iron chelator |
| A3356 | Delafloxacin | 189279-58-1 | 99.81% | Fluoroquinolone antibiotic |
| A3357 | Delafloxacin meglumine | 352458-37-8 | 98.00% | Fluoroquinolone antibiotic agent |
| A3358 | Deltarasin | 1440898-61-2 | 98.00% | KRAS-PDEδ interaction inhibitor |
| A3359 | Desmopressin | 16679-58-6 | 98.66% | Hemostatic and anti-diuretic |
| A3360 | Desmopressin Acetate | 62288-83-9 | 98.73% | Synthetic analogue of arginine vasopressin |
| A3363 | DGAT-1 inhibitor | 701232-20-4 | 99.64% | Diacylglycerol acyltransferase (DGAT1) inhibitor |
| A3366 | Dipraglurant | 872363-17-2 | 98.00% | mGluR5 antagonist |
| A3368 | DMAT | 749234-11-5 | 98.60% | CK2 inhibitor,potent and selective |
| A3369 | DMP 777 | 157341-41-8 | 98.00% | Leukocyte elastase (HLE) inhibitor |
| A3370 | Docetaxel Trihydrate | 148408-66-6 | 99.78% | Depolymerisation of microtubules inhibitor |
| A3371 | Doramectin | 117704-25-3 | 97.08% | Antiparasitic antibiotic |
| A3374 | Dronedarone | 141626-36-0 | 99.58% | CYP3A4 and 2D6 inhibitor,moderate |
| A3375 | DY131 | 95167-41-2 | 99.82% | ERRγ agonist |
| A3378 | E-3810 | 1058137-23-7 | 98.00% | VEGF/FGF dual inhibitor, potent and selective |
| A3380 | Ebrotidine | 100981-43-9 | 98.00% | H2-receptor antagonist,competitive |
| A3381 | Edoxaban | 480449-70-5 | 99.27% | Factor Xa inhibitor |
| A3383 | Edoxaban tosylate monohydrate | 1229194-11-9 | 99.34% | Oral factor Xa inhibitor |
| A3384 | Elacridar | 143664-11-3 | 98.17% | BCRP inhibitor |
| A3385 | Elacridar hydrochloride | 143851-98-3 | 98.00% | BCRP and P-GP inhibitor |
| A3387 | Eltrombopag Olamine | 496775-62-3 | 98.49% | C-mpl agonist |
| A3389 | EMD638683 | 1181770-72-8 | 98.46% | SGK1 inhibitor |
| A3392 | Emodin | 518-82-1 | 99.09% | Naturally occurring anthraquinone,antiproliferative |
| A3394 | Epothilone D | 189453-10-9 | 98.00% | Natural polyketide compound |
| A3395 | Ercalcidiol | 21343-40-8 | 98.00% | Vitamin D2 metabolite,ligand of VDR-like receptors |
| A3396 | Ercalcitriol | 60133-18-8 | 98.00% | Active metabolite of vitamin D2 |
| A3397 | Erlotinib | 183321-74-6 | 99.47% | EGFR tyrosine kinase inhibitor |
| A3399 | Esomeprazole Magnesium trihydrate | 217087-09-7 | 98.32% | Proton pump inhibitor |
| A3401 | Etifoxine hydrochloride | 56776-32-0 | 99.87% | GABAA receptor potentiator |
| A3403 | Etofenamate | 30544-47-9 | 98.05% | Non-steroidal anti-inflammatory drug |
| A3404 | Etomoxir | 124083-20-1 | 99.75% | (CPT)-1 and DGAT activity inhibitor |
| A3405 | Etoricoxib | 202409-33-4 | 99.82% | Specific COX-2 inhibitor |
| A3407 | EVP-6124 hydrochloride | 550999-74-1 | 99.85% | Alpha7 nAChR agonist |
| A3408 | Exendin-4 | 141758-74-9 | 99.66% | GLP-1 activator |
| A3411 | Faropenem daloxate | 141702-36-5 | 98.00% | Oral penem,beta-lactam antibiotic |
| A3412 | Fenretinide | 65646-68-6 | 98.00% | Synthetic retinoid agonist |
| A3413 | FH535 | 108409-83-2 | 99.62% | Wnt/B-catenin inhibitor |
| A3415 | Firategrast | 402567-16-2 | 99.56% | α4β1/α4β7 integrin antagonist |
| A3416 | FK 3311 | 116686-15-8 | 98.00% | Selective COX-2 inhibitor |
| A3417 | Flavopiridol | 146426-40-6 | 99.52% | Pan-cdk inhibitor |
| A3418 | Flecainide acetate | 54143-56-5 | 99.82% | Antiarrhythmic drug |
| A3419 | Fluvastatin | 93957-54-1 | 98.33% | HMGCR inhibitor |
| A3420 | FMK | 821794-92-7 | 98.82% | RSK inhibitor |
| A3421 | Fosamprenavir Calcium Salt | 226700-81-8 | 99.71% | Prodrug of antiretroviral protease inhibitor amprenavir |
| A3423 | Galanthamine | 357-70-0 | 99.12% | Acetylcholinesterase inhibitor |
| A3424 | Gambogic Acid | 2752-65-0 | 98.54% | Caspase activator and apoptosis inducer |
| A3429 | GANT 58 | 64048-12-0 | 99.38% | GLI antagonist,novel and potent |
| A3432 | GDC-0941 dimethanesulfonate | 957054-33-0 | 99.78% | PI3K inhibitor |
| A3433 | Gefitinib hydrochloride | 184475-55-6 | 99.87% | Potent EGFR inhibitor |
| A3434 | Genz-644282 | 529488-28-6 | 98.00% | Non-camptothecin inhibitor of topoisomerase I |
| A3435 | glucagon receptor antagonists 1 | 503559-84-0 | 98.00% | Glucagon receptor antagonist,highly potent |
| A3436 | glucagon receptor antagonists 2 | 202917-18-8 | 98.00% | Glucagon receptor antagonist,highly potent |
| A3437 | glucagon receptor antagonists 3 | 202917-17-7 | 98.00% | Glucagon receptor antagonist |
| A3438 | Glucocorticoid receptor agonist | 1245526-82-2 | 98.00% | Glucagon receptor antagonist |
| A3440 | Glyoxalase I inhibitor | 221174-33-0 | 98.00% | Glyoxalase I inhibitor |
| A3441 | GPR120 modulator 1 | 1050506-75-6 | 98.00% | GPR120 modulator |
| A3442 | GPR120 modulator 2 | 1050506-87-0 | 98.00% | GPR120 modulator |
| A3443 | Granisetron | 109889-09-0 | 98.00% | Serotonin 5-HT3 receptor antagonist |
| A3444 | GS-9620 | 1228585-88-3 | 98.01% | TLR-7 agonist |
| A3445 | GSK 525768A | 1260530-25-3 | 98.00% | inactive stereoisomer of I-BET-762 |
| A3446 | GSK126 | 1346574-57-9 | 98.32% | EZH2 inhibitor |
| A3448 | GSK2606414 | 1337531-36-8 | 98.18% | PERK inhibitor,potent and selective |
| A3449 | GSK343 | 1346704-33-3 | 98.95% | EZH2 inhibitor,potent,selective and cell permeable |
| A3450 | GSK-923295 | 1088965-37-0 | 98.28% | CENP-E inhibitor,small-molecule |
| A3451 | Guanfacine hydrochloride | 29110-48-3 | 99.41% | α2A-adrenoceptor agonist |
| A3452 | GW-1100 | 306974-70-9 | 98.00% | GPR40 antagonist |
| A3453 | GW1929 | 196808-24-9 | 98.00% | Potent PPARγ agonist |
| A3454 | GW3965 | 405911-09-3 | 98.00% | HLXRα/hLXRβ agonist,potent and selective |
| A3456 | GW843682X | 660868-91-7 | 98.00% | PLK1/PLK3 inhibitor,potent and selective |
| A3460 | HhAntag | 496794-70-8 | 98.95% | GLI1-mediated transcription inhibitor |
| A3461 | HIV-1 integrase inhibitor | 544467-07-4 | 98.00% | Uesful for anti-HIV |
| A3465 | HOE 33187 | 23623-08-7 | 98.00% | Blue fluorescent dyes |
| A3466 | Hoechst 33258 | 23491-45-4 | 99.88% | Blue fluorescent dyes |
| A3472 | Hoechst 33342 | 875756-97-1 | 98.84% | Blue fluorescent dyes |